Technical Briefing on Traditional Knowledge and Biopharmaceutical Innovation
Date
11 May 2011
Time
13:15 to 14:45
Location
World Intellectual Property Organization, Room B
Attend
This event has now passed. To browse our upcoming events click here.
The biopharmaceutical industry share a common interest with indigenous and local communities in greater transparency, predictability, and a balance of benefits against costs in protecting Traditional Knowledge (TK) at both the national and international level. The IFPMA organized a briefing to improve understanding of this complex issue by highlighting concrete experiences of the biopharmaceutical industry.
Program
Lunch
Welcome & Introduction
Mr. Andrew Jenner
Director, Innovation,
Intellectual Property and Trade
IFPMA, Geneva
The Rosy Periwinkle:
Myth, Fact and the Role of
Independent Scientifi c Research
Dr. Manisha A. Desai
Assistant General Patent Counsel
Eli Lilly and Company
Indianapolis
Q & A and Discussion
Speakers
Manisha A. Desai is Assistant General Patent Counsel at Eli Lilly and Company,
Indianapolis, Indiana. Since joining Lilly’s patent division in 1999, she has worked on the
procurement and enforcement of patents worldwide. She currently manages patent litigation
in the United States and in various emerging markets, including Latin America, Russia, the
Middle East, and South Asia.
Prior to practicing law, Manisha conducted biochemistry and neuroscience research for
almost 10 years in both university and industry settings. She obtained a law degree from
Indiana University School of Law, Bloomington, Indiana; a PhD in pharmacology from Emory
University, Atlanta, Georgia; and a BA in chemistry and Russian from Duke University,
Durham, North Carolina.
Andrew Jenner is Director of Innovation, Intellectual Property (IP) & Trade at the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). He is responsible for developing pharmaceutical industry strategy on Intellectual Property policy and represents the industry on IP and trade related issues within the UN and the World Trade Organization. He also leads a team of policy experts on trade, biotherapeutics and influenza vaccines. From 2007 until 2009 he was a Senior Policy Advisor and Head of the IP Crime Policy Group for the UK Intellectual Property Office (IPO), bringing together Government departments, Enforcement agencies and Industry to combat Intellectual Property Crime. From 2004 – 2007 he was Head of Trade & Development at the IPO and lead the IP discussions within the World Trade Organization (WTO), the World Health Organization (WHO) and World Intellectual Property Organization’s (WIPO) Intergovernmental Committee on genetic resources. He also led on policy relating to EU/UK IP pharmaceutical regulations, including negotiating the EU Regulation on the compulsory licensing of pharmaceutical products for export, and implementation of the EU ‘bolar exemption’ and Paediatric Medicines Regulation into UK law. He first joined the UK Government in 1998 as a patent examiner having previously worked in the automotive industry as a quality control advisor. He remains a member of the Institute of Engineering and Technology having a Bachelor degree in Engineering and a Master of Laws.